Advanced

Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study.

Gunnlaugsson, Adalsteinn LU ; Anderson, Harald LU ; Fernebro, Eva LU ; Kjellén, Elisabeth LU ; Byström, Per; Berglund, Ke; Ekelund, Mats LU ; Påhlman, Lars; Holm, Torbjörn and Glimelius, Bengt, et al. (2009) In European Journal of Cancer 45. p.807-813
Abstract
AIMS: This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma. PATIENTS AND METHODS: Forty-nine patients entered the trial. Two cycles of XELOX (capecitabine 1000mg/m(2) bid d1-14+oxaliplatin 130mg/m(2) d1, q3w) were followed by radiotherapy (50.4Gy), combined with capecitabine 825mg/m(2) bid every radiotherapy day and oxaliplatin 60mg/m(2) once weekly. The primary end-point was objective response. RESULTS: Forty-seven patients were evaluable. Twenty-nine (62% [95% CI: 46-75%]) achieved complete or partial response. Thirty-eight (81%) went through surgery of whom 37 (97%) had an R0 resection and five (13%) had a pathological complete response.... (More)
AIMS: This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma. PATIENTS AND METHODS: Forty-nine patients entered the trial. Two cycles of XELOX (capecitabine 1000mg/m(2) bid d1-14+oxaliplatin 130mg/m(2) d1, q3w) were followed by radiotherapy (50.4Gy), combined with capecitabine 825mg/m(2) bid every radiotherapy day and oxaliplatin 60mg/m(2) once weekly. The primary end-point was objective response. RESULTS: Forty-seven patients were evaluable. Twenty-nine (62% [95% CI: 46-75%]) achieved complete or partial response. Thirty-eight (81%) went through surgery of whom 37 (97%) had an R0 resection and five (13%) had a pathological complete response. Seventy-eight percent were alive and estimated local progression rate was 11% at 2 years. The most common grade 3+ toxicity during chemoradiotherapy was diarrhoea (24%). CONCLUSIONS: XELOX-RT was feasible and showed promising efficacy when treating patients with primary inextirpable colorectal cancer, establishing high local control rate. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Cancer
volume
45
pages
807 - 813
publisher
IFAC & Elsevier Ltd.
external identifiers
  • wos:000266205900021
  • pmid:19110416
  • scopus:61349133459
ISSN
1879-0852
DOI
10.1016/j.ejca.2008.11.017
language
English
LU publication?
yes
id
ab403b07-7cd1-479e-8c23-650e9debd76d (old id 1275898)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19110416?dopt=Abstract
date added to LUP
2009-01-09 14:21:22
date last changed
2017-01-01 07:29:04
@article{ab403b07-7cd1-479e-8c23-650e9debd76d,
  abstract     = {AIMS: This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma. PATIENTS AND METHODS: Forty-nine patients entered the trial. Two cycles of XELOX (capecitabine 1000mg/m(2) bid d1-14+oxaliplatin 130mg/m(2) d1, q3w) were followed by radiotherapy (50.4Gy), combined with capecitabine 825mg/m(2) bid every radiotherapy day and oxaliplatin 60mg/m(2) once weekly. The primary end-point was objective response. RESULTS: Forty-seven patients were evaluable. Twenty-nine (62% [95% CI: 46-75%]) achieved complete or partial response. Thirty-eight (81%) went through surgery of whom 37 (97%) had an R0 resection and five (13%) had a pathological complete response. Seventy-eight percent were alive and estimated local progression rate was 11% at 2 years. The most common grade 3+ toxicity during chemoradiotherapy was diarrhoea (24%). CONCLUSIONS: XELOX-RT was feasible and showed promising efficacy when treating patients with primary inextirpable colorectal cancer, establishing high local control rate.},
  author       = {Gunnlaugsson, Adalsteinn and Anderson, Harald and Fernebro, Eva and Kjellén, Elisabeth and Byström, Per and Berglund, Ke and Ekelund, Mats and Påhlman, Lars and Holm, Torbjörn and Glimelius, Bengt and Johnsson, Anders},
  issn         = {1879-0852},
  language     = {eng},
  pages        = {807--813},
  publisher    = {IFAC & Elsevier Ltd.},
  series       = {European Journal of Cancer},
  title        = {Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study.},
  url          = {http://dx.doi.org/10.1016/j.ejca.2008.11.017},
  volume       = {45},
  year         = {2009},
}